Funding for this research was provided by:
National Institutes of Health (U01 AG024904)
U.S. Department of Defense (W81XWH-12-2-0012)
Received: 17 September 2018
Accepted: 17 January 2019
First Online: 31 January 2019
Ethics approval and consent to participate
: The Partners Healthcare Institutional Review Board (IRB) approved the study, as did the IRB of each Alzheimer’s Disease Neuroimaging Initiative (ADNI) site. Written informed consent was obtained from all participants prior to initiation of any study procedures in accordance with IRB guidelines.
: Not applicable
: The authors have received research salary support from Eisai Inc. (GAM), Eli Lilly and Company (GAM, KAJ, RAS), Janssen Alzheimer Immunotherapy (DMR, GAM, KAJ, RAS), Avid Radiopharmaceuticals (KAJ, RAS), Navidea (KAJ), and Pfizer (KAJ). Additionally, DMR has served as a consultant for Eli Lilly, Neurotrack, Biogen, and Lundbeck Pharmaceuticals; GAM has served as a consultant for Grifols Shared Services North America, Inc. and Pifzer; KAJ has served as a consultant for Bayer, GE Healthcare, Janssen Alzheimer’s Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie; and RAS has served as a consultant for AbbVie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.